Share price close 16 Nov 2026
Quarterly or annual report filed
Quarterly or annual report filed
In one paragraph
Mettler Toledo reported revenue of $4.03 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 4.0% from fiscal 2024. Net income was $869 million and diluted earnings per share $42.05.
In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 30 Sep 2026), revenue was $1.09 billion, up 6.3% from a year earlier.
Figures from Mettler Toledo's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 6 Nov 2026.
Fiscal 2025 against fiscal 2024; bars show the last 10 fiscal years; net debt is borrowings and operating lease liabilities less cash and short-term investments at the year end.
| Segment | Revenue | Share | Change |
|---|---|---|---|
| US Operations | $1.50B | 37% | +4.7% |
| Western European Operations | $896.0M | 22% | +4.4% |
| Other Operations | $788.5M | 20% | +6.9% |
| Chinese Operations | $634.8M | 16% | +1.0% |
| Swiss Operations | $210.9M | 5.2% | −3.5% |
Mettler Toledo beside the other S&P 500 members in Life Sciences Tools & Services, by market value.
| Company | Market value | Day | 1 year | Revenue growth | Net margin | P/E |
|---|---|---|---|---|---|---|
| — | +0.5% | +20.1% | — | — | — | |
| $163.0B | +0.4% | +6.2% | +5.5% | 16.9% | 37.6 | |
| $48.72B | +0.5% | +14.8% | +8.6% | 19.5% | 33.8 | |
| $43.52B | −2.2% | +20.0% | +8.8% | 8.1% | 31.2 | |
| IlluminaILMN | $30.43B | −4.2% | +65.3% | +5.8% | 19.7% | 34.0 |
| $16.06B | −0.8% | +97.1% | −1.2% | 1.0% | 399.6 | |
| Bio-TechneTECH | — | −0.1% | +18.6% | — | — | — |
Market value and moves at the latest close. Revenue growth compares the last twelve months with the twelve before; net margin and P/E over the last twelve months; P/E is left blank where earnings are negative.
Fiscal years, as the company cuts its revenue in its annual reports; the change on a year under each figure. A change is left out from a loss, from a sliver of revenue, or across a change in how the company reports.
| Revenue | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| US Operations | $1.29B | $1.44B+12.1% | $1.40B−2.8% | $1.43B+1.8% | $1.50B+4.7% |
| Western European Operations | $829.8M | $799.9M−3.6% | $792.9M−0.9% | $858.0M+8.2% | $896.0M+4.4% |
| Other Operations | $656.9M | $657.7M+0.1% | $684.0M+4.0% | $737.8M+7.9% | $788.5M+6.9% |
| Chinese Operations | $771.7M | $841.5M+9.1% | $718.8M−14.6% | $628.4M−12.6% | $634.8M+1.0% |
| Swiss Operations | $171.6M | $176.1M+2.6% | $188.7M+7.1% | $218.6M+15.8% | $210.9M−3.5% |
| Total revenue | $3.72B | $3.92B | $3.79B | $3.87B | $4.03B |
| Revenue | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Laboratory products and services | $2.08B | $2.23B+7.1% | $2.07B−7.2% | $2.19B+5.7% | $2.24B+2.5% |
| Industrial products and services | $1.45B | $1.51B+4.4% | $1.49B−1.3% | $1.49B−0.0% | $1.58B+6.0% |
| Retail products and services | $188.4M | $178.8M−5.1% | $229.1M+28.1% | $196.4M−14.3% | $205.9M+4.9% |
| Total revenue | $3.72B | $3.92B | $3.79B | $3.87B | $4.03B |
Fiscal years, the latest ending 31 Dec 2025. Amounts in USD. On a narrow screen the table opens on the latest year and scrolls back.
| Period | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.51B | $2.73B | $2.94B | $3.01B | $3.09B | $3.72B | $3.92B | $3.79B | $3.87B | $4.03B |
| Revenue growth | +4.7% | +8.6% | +7.7% | +2.5% | +2.5% | +20.5% | +5.4% | −3.4% | +2.2% | +4.0% |
| Gross profit | $1.44B | $1.58B | $1.68B | $1.74B | $1.80B | $2.17B | $2.31B | $2.24B | $2.33B | $2.39B |
| Operating income | $530.9M | $597.1M | $664.6M | $712.6M | $773.5M | $989.5M | $1.12B | $1.05B | $1.11B | $1.10B |
| Net income | $384.4M | $376.0M | $512.6M | $561.1M | $602.7M | $769.0M | $872.5M | $788.8M | $863.1M | $869.2M |
| Diluted EPS | $14.22 | $14.24 | $19.88 | $22.47 | $24.91 | $32.78 | $38.41 | $35.90 | $40.48 | $42.05 |
| Gross margin | 57.3% | 57.8% | 57.4% | 57.9% | 58.4% | 58.4% | 58.9% | 59.2% | 60.1% | 59.4% |
| Operating margin | 21.2% | 21.9% | 22.6% | 23.7% | 25.1% | 26.6% | 28.5% | 27.6% | 28.6% | 27.3% |
| Net margin | 15.3% | 13.8% | 17.5% | 18.6% | 19.5% | 20.7% | 22.3% | 20.8% | 22.3% | 21.6% |
| Period | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $460.8M | $516.3M | $565.0M | $603.5M | $724.7M | $908.8M | $859.1M | $965.9M | $968.3M | $955.8M |
| Capital expenditure | $124.0M | $127.4M | $142.7M | $97.34M | $92.49M | $107.6M | $121.2M | $105.3M | $103.9M | $107.1M |
| Free cash flow | $336.8M | $388.9M | $422.3M | $506.1M | $632.2M | $801.2M | $737.8M | $860.6M | $864.4M | $848.6M |
| Period | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $158.7M | $148.7M | $178.1M | $207.8M | $94.25M | $98.56M | $95.97M | $69.81M | $59.36M | $66.89M |
| Total debt | $894.0M | $979.8M | $1.03B | $1.38B | $1.43B | $1.80B | $2.13B | $2.20B | $2.13B | $2.27B |
| Shareholders' equity | $434.9M | $547.3M | $590.1M | $420.8M | $282.7M | $171.4M | $24.79M | −$149.9M | −$126.9M | −$23.64M |
| Diluted shares | 27.0M | 26.4M | 25.8M | 25.0M | 24.2M | 23.5M | 22.7M | 22.0M | 21.3M | 20.7M |
The last eight fiscal quarters, the latest ending 30 Sep 2026. Year-on-year growth compares the same quarter of the previous fiscal year.
| Period | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.05B | $883.7M | $983.2M | $1.03B | $1.13B | $947.1M | $1.03B | $1.09B |
| Revenue, year on year | +11.8% | −4.6% | +3.9% | +7.9% | +8.1% | +7.2% | +4.5% | +6.3% |
| Gross margin | 61.2% | 59.5% | 59.0% | 59.2% | 59.8% | 58.7% | 63.3% | 59.8% |
| Operating income | $331.6M | $215.8M | $262.2M | $283.9M | $338.8M | $219.3M | $309.0M | $310.1M |
| Net income | $252.3M | $163.6M | $202.3M | $217.5M | $285.8M | $169.5M | $232.9M | $246.0M |
| Diluted EPS | $11.96 | $7.81 | $9.76 | $10.57 | $13.97 | $8.33 | $11.55 | $12.29 |
| Free cash flow | $224.9M | $177.2M | $212.5M | $274.9M | $184.1M | $122.4M | $282.6M | $281.5M |
The operating figures Mettler Toledo reports beside its statements, then its revenue by product, segment and region, latest period first. Each links to its full history.
| KPI | Latest | Period | Change on a year | Recent periods |
|---|---|---|---|---|
| Product revenue | $814.2M | quarter to 30 Sep 2026 | up 6.2% | |
| Laboratory products and services revenue | $599.8M | quarter to 30 Sep 2026 | up 6.2% | |
| Laboratory Related Products and Services revenue | $524.6M | quarter to 31 Mar 2026 | up 4.9% | |
| Industrial products and services revenue | $436.6M | quarter to 30 Sep 2026 | up 7.4% | |
| Industrial Related Products and Services revenue | $374.6M | quarter to 31 Mar 2026 | up 9.8% | |
| Service revenue | $280.1M | quarter to 30 Sep 2026 | up 6.5% | |
| Retail products and services revenue | $57.9M | quarter to 30 Sep 2026 | down 1.1% | |
| Retail Related Products and Services revenue | $47.9M | quarter to 31 Mar 2026 | up 13.2% | |
| US Operations revenue | $390.4M | quarter to 30 Sep 2026 | up 1.2% | |
| Us Operations segment Member revenue | $348.5M | quarter to 31 Mar 2026 | up 0.8% | |
| Western European Operations revenue | $228.9M | quarter to 30 Sep 2026 | up 0.7% | |
| Western European Operations Segment revenue | $215.4M | quarter to 31 Mar 2026 | up 13.1% | |
| Chinese Operations revenue | $200.8M | quarter to 30 Sep 2026 | up 20.2% | |
| Chinese Operations Segment revenue | $153.5M | quarter to 31 Mar 2026 | up 8.8% | |
| Swiss Operations revenue | $55.3M | quarter to 30 Sep 2026 | up 6.1% | |
| Swiss Operations segment Member revenue | $50.8M | quarter to 31 Mar 2026 | up 7.3% |
Each period is read from the report the company filed and checked against accounting identities before it is shown; a figure that does not pass is left blank rather than estimated. Free cash flow is operating cash flow less capital expenditure. Fiscal years follow the company's own calendar. See data and methodology.
The same figures as plain text and JSON.
$4.03 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), as reported in its annual report.
$869 million for fiscal year 2025 (the twelve months to 31 Dec 2025).
$42.05 for fiscal year 2025 (the twelve months to 31 Dec 2025).
59.4% for fiscal year 2025 (the twelve months to 31 Dec 2025): gross profit divided by revenue.
27.3% for fiscal year 2025 (the twelve months to 31 Dec 2025): operating income divided by revenue.
$849 million for fiscal year 2025 (the twelve months to 31 Dec 2025): operating cash flow less capital expenditure.
In fiscal 2025, by segment: US Operations $1.50B (37%), Western European Operations $896.0M (22%), Other Operations $788.5M (20%), Chinese Operations $634.8M (16%), out of $4.03B in all, as stated in its annual report.
In the terminal